The study did not meet its primary endpoint of chorea improvement or key secondary endpoints at the time of analysis. Topline data were announced from a phase 3 trial evaluating valbenazine in ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. The company’s Ingrezza (valbenazine), approved to treat certain uncontrolled movement ...

Cerebral palsy is a common disorder caused by a disturbance to the fetal or newborn brain. The injury usually occurs before birth or shortly thereafter, but signs of cerebral palsy may not be visible ...